# Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

> **NCT03610490** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Malignant Solid Neoplasm
- Metastatic Colorectal Adenocarcinoma
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Platinum-Resistant Ovarian Carcinoma
- Recurrent High Grade Ovarian Serous Adenocarcinoma
- Recurrent Ovarian Carcinosarcoma
- Refractory Colorectal Carcinoma
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Autologous Tumor Infiltrating Lymphocytes MDA-TIL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Interleukin-2
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03610490
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-16
- **Primary completion:** 2024-08-21
- **Final completion:** 2024-08-21
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2025-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610490, "Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03610490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*